Headache is one of the most frequently reported adverse events in clinical trials where PPIs have been examined (frequency 1.3-8.8%). Patients with headache also had a significant incidence of diarrhea, nausea, and dizziness. A discontinuation of PPI therapy resulted in a cessation or reduction of the headache in 80.0% (20 of 25) (156).
Possible risks of prolonged treatment with PPIs had been thought to include hypergas-trinemia (157), atrophic gastritis, and enteric infections. However, no data have established any true risk to patients, despite many years
Table 3.6 An Overview of the Clinically Marketed PPI Inhibitors; Affinity, Clinical Pharmacology, and Pharmacokinetic Profile
Clinical Pharmacology: Effect on Gastric Acid Secretion
Plasma Half-Life (h)
Volume of Distribution (Lkg"1)
Plasma Protein Binding
Pantoprazole 8.6 (208)
Lansoprazole 9 (208)
Was this article helpful?